Rubin Jonathan 4

4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Feb 25, 2026

Form 4

Period: 2026-02-24

SVP, Chief Medical Officer

Transactions

Award
Common Stock
2026-02-24+1,125→ 12,409 total
Tax Payment
Common Stock
[F1]
2026-02-24$51.35/sh−603$30,964→ 11,806 total
Award
Common Stock
2026-02-24+750→ 12,556 total
Tax Payment
Common Stock
[F1]
2026-02-24$50.86/sh−369$18,767→ 12,187 total
Award
Common Stock
2026-02-24+1,250→ 13,437 total
Tax Payment
Common Stock
[F1]
2026-02-24−671→ 12,766 total
Disposition to Issuer
Restricted Stock Unit
[F2][F3]
2026-02-24−1,125→ 3,375 total
→ Common Stock (1,125 underlying)
Disposition to Issuer
Restricted Stock Unit
[F2][F4]
2026-02-24−750→ 0 total
→ Common Stock (750 underlying)
Disposition to Issuer
Restricted Stock Unit
[F2][F5]
2026-02-24−1,250→ 2,500 total
→ Common Stock (1,250 underlying)

Footnotes (5)

[F1]Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
[F2]Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
[F3]These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
[F4]These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023.
[F5]These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.

Signature

/s/ Timothy C. Dec, as attorney-in-fact|2026-02-25

Documents

1 file